BrightEdge operates at the intersection of investment and innovation to define and catalyze scientific, social, and sustainable impact across the continuum of cancer care.
Employees: 11-50
Investment Type: Venture Capital
Portfolio 17
| Date | Name | Website | Total Raised | Location |
| - | Castle Bio... | castlebiosciences.com | $43.6M | United Sta... |
| - | Interius | interiusbio.com | $76M | United Sta... |
| - | Mercy BioA... | mercybio.com | $100M | United Sta... |
| - | Lunit | lunit.io | $237M | South Kore... |
| - | Checkmate ... | checkmatepharma.com | $154M | United Sta... |
| - | TailorMed | tailormed.co | $85M | United Sta... |
| - | Freenome | freenome.com | $1.05B | United Sta... |
| - | Immunitas ... | immunitastx.com | $97M | United Sta... |
| - | CellCentri... | cellcentric.com | $171M | United Kin... |
| - | Naveris, I... | naveris.com | $51M | United Sta... |
Show more
News 30
| Date | Title | Description |
| 26.12.2024 | BrightEdge Annual Report 2023 | Click the red "View Report" link to read the full report |
| 18.09.2024 | Advancing Impact: A BrightEdge Roundtable and White Paper | The cancer and health care landscape is rapidly evolving, demanding innovative solutions and strategic investments to address key challenges. This white paper offers a comprehensive overview of the insights and discussions from BrightEdge's... |
| 03.11.2023 | BrightEdge Annual Report 2022 | Click the red "View Report" link to read the full report |
| 03.11.2023 | CellCentric to present haem clinical data at ASH | Cambridge, UK, November 4th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces that the Chief Investigator of its haematological mal... |
| - | Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers | Wellesley, Mass., Jan. 27, 2021 – Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proc... |
| - | American Cancer Society’s Impact Venture Capital Arm Secures $1 Million in New Contributions | For more information, contact: Michele Money-Carson michele.money-carson@cancer.org |
| - | American Cancer Society’s BrightEdge to Invest in Checkmate Pharmaceuticals | BrightEdge, LLC, the American Cancer Society’s philanthropic impact fund, today announced its participation in the Series C funding round of Checkmate Pharmaceuticals (www.checkmatepharma.com), a clinical stage biopharmaceutical company foc... |
| - | BrightEdge Receives $1.25 Million Grant from WoodNext Foundation to Launch Entrepreneurship Fellows Program | BOSTON, February 1, 2023 –BrightEdge, the impact venture capital arm of the American Cancer Society (ACS), has received a $1.25 million grant from the WoodNext Foundation, a donor-advised fund sponsored by the Greater Houston Community Foun... |
| - | Persephone Biosciences and Ginkgo Bioworks Announce Collaboration to Develop Novel Therapeutics | Bacteroides species are among the most common members of the microbiota of animals, especially in the gastrointestinal tract, and are likely a useful tool for stable and long-term delivery of microbial medicines. Unlike many other gut micro... |
| - | Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic | Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medic... |
Show more
Mentions in press and media 5
| Date | Title | Description |
| 02.10.2025 | Predicta Biosciences Raises $23.4M in Series A Funding | Predicta Biosciences, a Cambridge, MA-based precision oncology company developing novel diagnostic and therapeutic discovery solutions, raised $23.4m in Series A funding. The round was led by Engine Ventures with particiaption from Illumina... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know: – Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 22.08.2023 | BrightEdge’s Impact: Transforming Cancer Care and Changing Lives | Key Takeaways: ACS BrightEdge’s annual report reveals its portfolio of 18 companies could potentially impact over 1.5 million lives by advancing cancer-focused therapies and technologies. The Cancer Impact Investing Framework (CIIF) guides ... |